JOHN MENDLEIN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JOHN MENDLEIN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JOHN MENDLEIN. JOHN MENDLEIN is Director in ACLARA BIOSCIENCES INC ($ACLA) and CEO & Executive Chariman in aTYR PHARMA INC ($LIFE) and CEO and Director in aTYR PHARMA INC ($LIFE) and CEO and Executive Chairman in aTYR PHARMA INC ($LIFE) and Director in aTYR PHARMA INC ($LIFE) and See Remarks in aTYR PHARMA INC ($LIFE) and Director in FATE THERAPEUTICS INC ($FATE) and Director in Editas Medicine, Inc. ($EDIT).
Latest Insider Trading Transactions of JOHN MENDLEIN
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACLA, LIFE, EDIT, FATE
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 05 2020 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 26.59 | 16,000 | 425,440 | 16,000 | |
May 10 2019 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | Director | Option Exercise | A | 0.58 | 20,000 | 11,668 | 20,000 | |
May 07 2019 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 17.15 | 16,000 | 274,400 | 16,000 | |
Dec 26 2018 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | Director | Buy | P | 0.42 | 195,000 | 82,602 | 615,382 | 420.4 K to 615.4 K (+46.39 %) |
Dec 26 2018 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | Director | Buy | P | 0.41 | 50,000 | 20,645 | 420,382 | 370.4 K to 420.4 K (+13.50 %) |
May 17 2018 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | Director | Option Exercise | A | 1.35 | 20,000 | 27,000 | 20,000 | |
May 04 2018 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 9.78 | 16,000 | 156,480 | 16,000 | |
Jan 02 2018 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | Director | Option Exercise | A | 3.80 | 32,000 | 121,600 | 32,000 | |
Sep 05 2017 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Option Exercise | P | 4.64 | 14,151 | 65,661 | 14,151 | |
Sep 05 2017 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 2.65 | 37,736 | 100,000 | 367,883 | 330.1 K to 367.9 K (+11.43 %) |
Jun 19 2017 | EDIT | Editas Medicine, I ... | MENDLEIN JOHN | Director | Option Exercise | A | 15.63 | 11,538 | 180,339 | 11,538 | |
May 04 2017 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 4.73 | 25,000 | 118,250 | 25,000 | |
Apr 26 2017 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 3.00 | 124 | 372 | 327,647 | 327.5 K to 327.6 K (+0.04 %) |
Apr 20 2017 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 3.00 | 1,552 | 4,656 | 327,523 | 326 K to 327.5 K (+0.48 %) |
Apr 20 2017 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 3.00 | 1,000 | 3,000 | 325,971 | 325 K to 326 K (+0.31 %) |
Dec 21 2016 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 2.20 | 69,000 | 151,662 | 324,971 | 256 K to 325 K (+26.96 %) |
May 13 2016 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 1.69 | 25,000 | 42,250 | 25,000 | |
Apr 07 2016 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 3.52 | 2,500 | 8,800 | 250,971 | 248.5 K to 251 K (+1.01 %) |
Apr 06 2016 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Buy | P | 3.55 | 2,500 | 8,875 | 248,471 | 246 K to 248.5 K (+1.02 %) |
Feb 04 2016 | EDIT | Editas Medicine, I ... | MENDLEIN JOHN | Director | Option Exercise | A | 16.00 | 96,153 | 1,538,448 | 96,153 | |
Jan 29 2016 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Option Exercise | A | 6.14 | 135,000 | 828,900 | 135,000 | |
Jan 06 2016 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Director | Option Exercise | A | 9.13 | 148,732 | 1,357,923 | 148,732 | |
Oct 05 2015 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | See Remarks | Option Exercise | A | 10.24 | 65,070 | 666,317 | 65,070 | |
Oct 05 2015 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | See Remarks | Option Exercise | A | 10.24 | 71,000 | 727,040 | 71,000 | |
May 15 2015 | FATE | FATE THERAPEUTICS ... | MENDLEIN JOHN | Director | Option Exercise | A | 7.08 | 10,000 | 70,800 | 10,000 | |
May 14 2015 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Executive C ... | Option Exercise | C | 0.00 | 21,122 | 0 | 0 | |
May 14 2015 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Executive C ... | Option Exercise | C | 0.00 | 170,218 | 0 | 0 | |
May 14 2015 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO and Executive C ... | Buy | C | 0.00 | 24,055 | 0 | 245,971 | 221.9 K to 246 K (+10.84 %) |
May 08 2015 | LIFE | aTYR PHARMA INC | MENDLEIN JOHN | CEO & Executive Cha ... | Option Exercise | A | 14.00 | 163,437 | 2,288,118 | 163,437 | |
Dec 10 2004 | ACLA | ACLARA BIOSCIENCES ... | MENDLEIN JOHN | Director | Option Exercise | D | 4.39 | 12,000 | 52,680 | 0 | |
Dec 10 2004 | ACLA | ACLARA BIOSCIENCES ... | MENDLEIN JOHN | Director | Option Exercise | D | 4.25 | 12,000 | 51,000 | 0 | |
Dec 10 2004 | ACLA | ACLARA BIOSCIENCES ... | MENDLEIN JOHN | Director | Option Exercise | D | 3.48 | 30,000 | 104,400 | 0 | |
Dec 10 2004 | ACLA | ACLARA BIOSCIENCES ... | MENDLEIN JOHN | Director | Option Exercise | D | 2.11 | 24,000 | 50,640 | 0 | |
Dec 10 2004 | ACLA | ACLARA BIOSCIENCES ... | MENDLEIN JOHN | Director | Option Exercise | A | 4.39 | 12,000 | 52,680 | 78,000 |
Page: 1